Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
aXichem AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-0.04.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.24.
During the past 3 years, the average EBIT per Share Growth Rate was 29.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 19.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 3.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for aXichem AB's EBIT per Share or its related term are showing as below:
OSTO:AXIC A'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -94.2 Med: -4.2 Max: 29.7
Current: 29.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of aXichem AB was 29.70% per year. The lowest was -94.20% per year. And the median was -4.20% per year.
OSTO:AXIC A's 3-Year EBIT Growth Rate is ranked better than 85.43% of 1338
companies
in the Chemicals industry
Industry Median: -1.15
vs OSTO:AXIC A: 29.70
aXichem AB's EBIT for the
three
months ended in Mar. 2026 was kr-2.83 Mil.
aXichem AB (OSTO:AXIC A) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
aXichem AB EBIT per Share Related Terms
aXichem AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for aXichem AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aXichem AB (OSTO:AXIC A) has a EBIT per Share of kr-0.24 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on aXichem AB and its competitors. According to the industry distribution chart, aXichem AB ranks #195 out of 1338 companies in the Chemicals industry, placing it in the top 14.6%.
Is aXichem AB's EBIT per Share too high?
aXichem AB's current EBIT per Share is kr-0.24. Based on the distribution chart, aXichem AB ranks #195 out of 1338 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, aXichem AB has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does aXichem AB's EBIT per Share compare to LIN and SHW?
According to the Chemicals industry distribution chart, aXichem AB ranks #195 out of 1338 companies for EBIT per Share. This places aXichem AB in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Chemicals company?
A good EBIT per Share depends on the Chemicals industry context. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on aXichem AB and its competitors. aXichem AB's current EBIT per Share is kr-0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aXichem AB stock overvalued right now?
Based on GuruFocus' analysis, aXichem AB (OSTO:AXIC A) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.59, compared to a current price of kr2.63 — trading 26.7% below its estimated fair value. The current EBIT per Share is kr-0.24. aXichem AB's overall GF Score™ is 66/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For aXichem AB (OSTO:AXIC A), the current EBIT per Share is kr-0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aXichem AB (OSTO:AXIC A) Overvalued in 2026?
Based on GuruFocus' analysis, aXichem AB stock appears to be undervalued.
The current stock price of kr2.63 is trading 26.7% below its estimated GF Value™ of kr3.59.
GuruFocus considers aXichem AB to be Modestly Undervalued.
Key valuation signals for OSTO:AXIC A:
EBIT per Share: kr-0.24
GF Value™: kr3.59 vs. price of kr2.63 (26.7% below fair value)
No single metric tells the full story. See the OSTO:AXIC A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aXichem AB develops, patents, markets and sells natural analogue industrial chemicals, which are synthetically produced substances with similar and comparable properties to natural substances. The Company's business concept is to develop, patent, market and sell natural analogue industrial chemicals. Its commercial focus is on the proprietary patented product phenylcapsaicin, the Company's first product, which is marketed under the registered trademarks aXiphen as an additive in animal feed and aXivite as an ingredient in food supplements and as a bioenhancer. The Company's product portfolio comprises Phenylcapsaicin, aXiphen, aXiphen bio, and aXivite. The Company's focus is on establishing aXiphen as an additive in poultry feed and pig feed.
66GF Score
Get the complete analysis for OSTO:AXIC A
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:AXIC A has been successfully added to your 
